Artificial Intelligence
Alpha Sigma Capital and Transform Ventures Create New Holding Company to Accelerate Blockchain Investment and Innovation, Launching Two New Funds
<!– Name:DistributionId Value:8784545 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:500114514 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9b6d4a8e-7e2c-4322-a38a-4199d1778e4d –>
MIAMI, FLORIDA, March 09, 2023 (GLOBE NEWSWIRE) — Alpha Sigma Capital, announced today an investment from Transform Ventures and its founder, Michael Terpin, into its new holding company, Alpha Transform Holdings.
Alpha Transform Holdings, Inc. (ATH) has been created by the merger of select assets from early blockchain investor and innovator Michael Terpin’s investment vehicle, Transform Ventures, and Alpha Sigma Capital’s parent company, creating a new holding company. The new company will also create two new funds with a total of $100 mm AUM.
The new assets include majority ownership in Content Syndicate, a Transform Ventures spin-out best known for its pioneering news service, BlockchainWire. Transform Strategies will also integrate its market-leading strategy and advisory services with Alpha Sigma’s existing research, strategy, and token financing facility offerings to create a powerful “one-stop shop” for digital asset companies, foundations, and projects of all sizes and orientations. The investment includes funding for the Alpha Transform Holdings parent company, the new Alpha Liquid digital asset fund, and a closed-end venture capital firm for early-stage equity investments in blockchain, AI, and emerging technology companies, the Aegean Fund.
Terpin also made a personal investment in cash, Bitcoin, and Ethereum of $2.65 million, with an option to invest an additional $2.9 million.
Alpha Sigma Capital launched in 2020, with a blockchain/Web3 founding fund that has successfully delivered alpha for the past three years, with a total fund performance of 1400 percent (14x capital invested). The Alpha Sigma Capital approach to investing is based on investing in high-performing teams, focusing on risk management, and focusing on results has proven out since inception.
“The ATH vision is to shepherd in a new era of financial and technological innovation leveraging decentralization, blockchain technology, and Web3 infrastructure,” said Enzo Villani, Alpha Transform Holdings CEO, and Chief Investment Officer. “The Alpha Transform model is to continue to support our portfolio companies with strategic advisory, acceleration, and capital to drive innovation and success.”
Michael Terpin commented, “Enzo and I have worked together in different capacities going back to NASDAQ’s strategic partnership with MarketWire, and then at Transform Group, where he expanded our Transform Strategies group. Officially combining these assets and advisory networks under one umbrella accelerates both businesses and our portfolio companies.”
ATH has three complementary areas of focus:
- Asset Management: Investment arm, including Alpha Sigma Capital Web3 Fund, Alpha Liquid, and Aegean Ventures.
- Alpha Transform Products: Alpha Sigma Capital Research, Blockchain Wire, and Content Syndicate distribution and market intelligence products service clients, portfolio managers, and our limited partners with content and data.
- Alpha Transform Strategies: A combined group led by Michael Terpin and Enzo Villani to provide end-to-end solutions for digital asset companies including management consulting, strategy, advisory, funding, and investor/token relations.
The ATH model leverages ”Buy and Build” strategies to create a diversified Web3 holding organization that assists its portfolio and balance sheet companies to manage the full lifecycle. The core business model focuses on three key objectives:
- Invest in Scale: Consolidation of blockchain economy companies that are in the growth phase including fintech, DeFi, CeFi, SaaS, and Dapps. Utilize both balance sheet and investment funds to acquire and invest in rising growth-oriented firms seeking scale.
- Innovate and Incubate: Develop strategies to invest in early-stage and incubate blockchain companies and Web3 applications. Build investments in top-tier seed to Series A funds, as well as Terpin’s global BitAngels investor network and CoinAgenda global blockchain investor conference series, to gain access to deal flow.
- Integration: ATH will create opportunities to service clients, investors, and stakeholders across multiple businesses and asset classes.
About Alpha Transform Holdings
Alpha Transform Holdings (ATH) is a new holding company created from the merger of strategic assets controlled by Enzo Villani of Alpha Sigma Capital and Michael Terpin of Transform Ventures. These assets include combining our market-leading advisory services with Alpha Sigma’s existing research, strategy, and token facility offerings to create a powerful “one-stop shop” for digital asset companies, foundations, and projects of all sizes and orientations. www.alphatransform.io
Alpha Sigma Capital Funds is a pioneering digital asset fund focused on the blockchain economy and the shift to a decentralized Web3 infrastructure. Alpha Sigma Capital invests in companies and decentralized projects that are leveraging blockchain technology to provide demonstrable change and efficiency in financial services, artificial intelligence, supply chain, gaming, healthcare technology, and ESG. Alpha Sigma Capital works closely with its founders to drive value and create outsized returns. The Fund’s research team is well known for its in-depth research and distinct analysis of growing blockchain companies. Apply to receive our research newsletter at www.alphasigma.fund/research.
Disclaimer / Regulation D 506c
FUND DISCLAIMER
ANY HISTORICAL PERFORMANCE DATA REPRESENTS PAST PERFORMANCE. PAST PERFORMANCE DOES NOT GUARANTEE FUTURE RESULTS; CURRENT PERFORMANCE MAY BE DIFFERENT THAN THE PERFORMANCE DATA PRESENTED; THE COMPANY IS NOT REQUIRED BY LAW TO FOLLOW ANY STANDARD METHODOLOGY WHEN CALCULATING AND REPRESENTING PERFORMANCE DATA; THE PERFORMANCE OF THE COMPANY MAY NOT BE DIRECTLY COMPARABLE TO THE PERFORMANCE OF OTHER PRIVATE OR REGISTERED FUNDS OR COMPANIES; THE SECURITIES ARE BEING OFFERED IN RELIANCE ON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS, AND THEREFORE ARE NOT REQUIRED TO COMPLY WITH CERTAIN SPECIFIC DISCLOSURE REQUIREMENTS; THE SECURITIES AND EXCHANGE COMMISSION HAS NOT PASSED UPON THE MERITS OF OR APPROVED THE SECURITIES, THE TERMS OF THE OFFERING, OR THE ACCURACY OF THE MATERIALS. THESE RESULTS HAVE NOT BEEN VERIFIED BY ANY THIRD PARTY INCLUDING A THIRD-PARTY AUDITOR.
NOT A SOLICITATION OR OFFER
This presentation is not an offer to sell or the solicitation of an offer to purchase any securities. Any such offer or solicitation would be made to accredited investors by means of a private placement memorandum and other documents that provide detailed information about the Alpha Sigma Capital Fund, LP. This presentation is not to be relied upon in any way by any person in evaluating an investment decision.
DISCLAIMER
This presentation and the information presented herein are strictly confidential and may not be distributed to any person or entity other than the recipients hereof. This presentation shall not constitute an offer to sell or the solicitation of any offer to buy interests in Alpha Sigma Capital which may only be made at the time a qualified offeree receives the applicable Alpha Sigma Capital’s confidential subscription documents and governing documents (collectively, the “Alpha Sigma Operative Documents”). The key Alpha Sigma Capital terms summarized in this presentation are not intended to be complete and material aspects of the terms may change over time. In the case of any inconsistency between the descriptions or terms in this presentation and the Alpha Sigma Operative Documents, the Alpha Sigma Operative Documents shall control. While the information prepared in this presentation is believed to be accurate, neither Alpha Sigma Capital (“Alpha Sigma”) nor any of its affiliates or representatives (i) makes any express or implied warranty as to the completeness or accuracy of this presentation, (ii) shall be liable for errors appearing in this presentation or (iii) has any duty to update this presentation or any of the information contained herein. There is no guarantee that the investment objective will be achieved. Past performance should not be construed as an indicator of future performance. Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue,” “target” or “believe” (or the negatives thereof) or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or actual performance of the funds may differ materially from those reflected or contemplated in such forward-looking statements. As a result, investors should not rely on such forward-looking statements in making their investment decisions. No representation or warranty is made as to future performance or such forward-looking statements. The information herein is not intended to provide, and should not be relied upon, accounting, legal or tax advice or investment recommendations. A recipient of this presentation should consult his or her tax, legal, accounting, or other advisors about the matters discussed herein. Alpha Sigma Capital may modify its investment approach in the future without notice to the investors in a manner that Alpha Sigma believes is consistent with Alpha Sigma Capital’s overall investment objectives. An investment in Alpha Sigma Capital is speculative and involves a high degree of risk. Opportunities for the transferability of interests of Alpha Sigma Capital will be restricted, so investors may not have access to capital when it is needed. No secondary market for the interests of Alpha Sigma Capital is expected to develop. Leverage may be employed which can make investment performance volatile. An investor should not make an investment unless it is prepared to lose all or a substantial portion of the investment. The fees and expenses charged in connection with this investment may be higher than the fees and expenses of other investment alternatives and may offset profits. The investment examples highlighted in this presentation are presented solely for illustrative purposes only.
CONTACT Information: [email protected]
Artificial Intelligence
Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times
Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.
“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html
Artificial Intelligence
Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data
ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html
Artificial Intelligence
Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe
Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.
As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html
-
Uncategorized7 days agoArtificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence5 days agoJapan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized6 days ago
Google to roll out AI-generated summaries at top of search engine
-
Uncategorized4 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence5 days agoStrava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days agoData Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence4 days agoMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days ago
IBM Expands Qiskit, World’s Most Performant Quantum Software
